TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2688940
Drug: Qigong therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qigong therapy with regularly antihypertensive drug taking (n = 50)
Study: 2688940
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with regularly antihypertensive drug taking only (n = 50)
Study: 31229087
Drug: Carotenoid-rich 'matrix-free'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotenoid-rich 'matrix-free' formulation (0.8 mg sapotexanthin, 1.2-1.5 mg cryptocapsin)
Study: 31229087
Drug: Fresh Mamey
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh Mamey sapote fruit (0.8 mg sapotexanthin, 1.2-1.5 mg cryptocapsin)
Study: 31229087
Drug: Both test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both test meals (fresh fruit and matrix-free formulation)
Study: 31229087
Drug: Carotenoid-rich 'matrix-free'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotenoid-rich 'matrix-free' formulation
Study: 23286463
Drug: Computerized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized treatment for insomnia
Study: 21569488
Drug: Group Cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Cognitive Behavioural Therapy (CBT) for 12 weeks
Study: 12032583
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous immunoglobulin G (IVIg)
Study: 10190913
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) therapy (10 ppm)
Study: 31792856
Drug: 15‐keto fluprostenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15‐keto fluprostenol (35 μg/ml)
Study: 25519996
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) alone (group B)
Study: 24079282
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin (0.5 g/d for 3 weeks, then 1 g/d)
Study: 21334569
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (alternative SSRI plus CBT)
Study: 21334569
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (venlafaxine plus CBT)
Study: 21334569
Drug: Medication mono-therapy
Normalized name: tiotropium bromide mono
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication mono-therapy
Study: 19243423
Drug: Levetiracetam (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (40 mg/kg/day for age 1 to <6 months; 50 mg/kg/day for age >or=6 months to <4 years)
Study: 17579892
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of flaxseed (FS) with soy protein or genistein (GEN) with enterodiol (END) and enterolactone (ENL)
Study: 14758212
Drug: Fibrin glue-anchored
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin glue-anchored Integra with postoperative negative-pressure therapy
Study: 7696887
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (50 mg every 3 weeks)
Study: 7696887
Drug: 1-alpha-hydroxy-calciferol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-alpha-hydroxy-calciferol (1 microgram daily)
Study: 7696887
Drug: Placebo (inactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (inactive drug)
Study: 3229387
Drug: Large-volume group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large-volume group (LVG) injected with up to 30 ml per session
Study: 3229387
Drug: Small-volume group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-volume group (SVG) injected with up to 15 ml per session
Study: 27515872
Drug: Withania somnifera
Normalized name: WITHANIA SOMNIFERA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withania somnifera extract (120 mg/day), n = 15
Study: 24974901
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml levobupivacaine 0.5%
Study: 24974901
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml saline 0.9% (control group)
Study: 22490197
Drug: Compound whole
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound whole grain and health education
Study: 20537611
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (n = 12)
Study: 7664702
Drug: Propofol 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 0.6 mg/kg
Study: 28506854
Drug: Solifenacin oral
Normalized name: solifenacin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin oral suspension
Study: 21804501
Drug: S. boulardii
Normalized name: Lactobac. plantarum/S. boulardii/Pediococcus acidilactici 8 billion cell ORAL CAPSULE,DELAYED RELEASE (ENTERIC COATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S. boulardii 250 mg twice daily orally for one month
Study: 11294478
Drug: Long-term lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-term lithium treatment (>6 months)
Study: 11294478
Drug: Short-term lithium
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term lithium treatment (<6 months)
Study: 29684148
Drug: JNJ‐53718678 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ‐53718678 75 mg
Study: 29684148
Drug: JNJ‐53718678 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ‐53718678 200 mg
Study: 29684148
Drug: JNJ‐53718678 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ‐53718678 500 mg
Study: 29684148
Drug: JNJ‐53718678 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ‐53718678 (all doses)
Study: 22573470
Drug: ENABLE II
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENABLE II concurrent oncology palliative care intervention
Study: 21914041
Drug: Lubiprostone (48
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubiprostone (48 μg day(-1) for 14 days)
Study: 17023239
Drug: Heat wrap
Normalized name: Softheat Ultra Back Heat Wrap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat wrap (treatment study, n=16)
Study: 14605043
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 micro g/d
Study: 8981288
Drug: Fluid Replacement
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid Replacement Trial (FR-trial) with water bolus of 3.0 ml kg‐1 body mass pre-exercise and 2.0 ml kg‐1 body mass every 15 min during exercise
Study: 3026273
Drug: Perindopril 4.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 4.8 mg
Study: 15570642
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy
Study: 3307570
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups with initial EVLW > 14 ml/kg
Study: 28173855
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for psychosocial distress
Study: 16940405
Drug: Oseltamivir 75
Normalized name: oseltamivir 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 75 mg (single oral dose)
Study: 11502787
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy/estrogen replacement therapy (conjugated estrogens 0.625 mg daily + medroxyprogesterone acetate 2.5 mg daily)
Study: 11502787
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hormone replacement therapy/estrogen replacement therapy + calcitriol
Study: 11502787
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy/estrogen replacement therapy alone
Study: 11502787
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (in adherent women)
Study: 3322468
Drug: Fluoxetine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (mean dose 73 mg each morning)
Study: 3322468
Drug: Amitriptyline (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (mean dose 122 mg at night)
Study: 29466533
Drug: Clinician coaching
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician coaching sessions (dosage)
Study: 29466533
Drug: Interaction between
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interaction between patient and clinician dosage
Study: 26827293
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus practice quitting program (N = 46)
Study: 26827293
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (N = 47)
Study: 22650122
Drug: Routine acupuncture
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine acupuncture therapy at Shenshu (BL 23)
Study: 18399768
Drug: Iodized oil
Normalized name: ethiodized oil
DrugBank: Ethiodized oil (DB00965)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodized oil administered orally
Study: 11135715
Drug: Intramuscular rapacuronium
Normalized name: rapacuronium
DrugBank: Rapacuronium (DB04834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular rapacuronium 2.8 mg/kg in infants
Study: 11135715
Drug: Intramuscular rapacuronium
Normalized name: rapacuronium
DrugBank: Rapacuronium (DB04834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular rapacuronium 4.8 mg/kg in children
Study: 11135715
Drug: Intramuscular rapacuronium
Normalized name: rapacuronium
DrugBank: Rapacuronium (DB04834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular rapacuronium (both doses)
Study: 7605424
Drug: Control patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control patients on warfarin (n = 31)
Study: 2731163
Drug: Oral supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplementation with beta-carotene (90 mg twice weekly for 4 weeks)
Study: 31139989
Drug: Anti-fog solution
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-fog solution
Study: 29739378
Drug: Serum 25-hydroxyvitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum 25-hydroxyvitamin D concentrations ≥30 ng/ml
Study: 29739378
Drug: Serum 25-hydroxyvitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum 25-hydroxyvitamin D concentrations <30 ng/ml
Study: 27271833
Drug: Interferential currents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferential currents for psoriasis treatment
Study: 27271833
Drug: Standard medicamentous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medicamentous therapy for psoriasis treatment
Study: 27271833
Drug: Interferential currents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferential currents for eczema treatment
Study: 27271833
Drug: Standard medicamentous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medicamentous therapy for eczema treatment
Study: 25331573
Drug: Antibiotic prescribing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prescribing
Study: 25331573
Drug: Antibiotic-resistant isolates
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic-resistant isolates
Study: 21028985
Drug: High-dose artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: High-dose artesunate therapy (4 mg/kg/day orally for 7 days)
Study: 15811479
Drug: Manidipine 10
Normalized name: manidipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manidipine 10 mg once daily for 24 weeks
Study: 15811479
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg once daily for 24 weeks
Study: 8974213
Drug: Fluvastatin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin therapy (20 mg twice daily)
Study: 8974213
Drug: Open-label adjunctive
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label adjunctive cholestyramine (for patients with mean prerandomization LDL cholesterol of 160 mg/dL or higher)
Study: 14621733
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists (CATs)
Study: 3830764
Drug: Diltiazem 120
Normalized name: diltiazem 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 120 mg every 8 hours for three consecutive days
Study: 3830764
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered with the same regimen
Study: 30819640
Drug: Pharmacist-provided medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-provided medication therapy management program
Study: 18269774
Drug: Albumin-bound paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin-bound paclitaxel 100 mg/m2
Study: 18269774
Drug: Albumin-bound paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin-bound paclitaxel 125 mg/m2
Study: 16223400
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% plus 0.5 mg/kg ketamine
Study: 16223400
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% plus 0.5 mg/kg ketamine
Study: 9163650
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline with 2 L x min(‐1) oxygen
Study: 9163650
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg morphine with 2 L x min(‐1) oxygen
Study: 9163650
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg morphine with 2 L x min(‐1) oxygen
Study: 9163650
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg morphine without oxygen (prongs fixed, no flow)
Study: 1973472
Drug: Methotrexate 15
Normalized name: methotrexate 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 15 mg weekly
Study: 4571398
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of terbutaline (0.075 mg/kg)
Study: 28768263
Drug: Saline rectal
Normalized name: Ready To Use Saline Rectal Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline rectal washout (RW)
Study: 28768263
Drug: Glycerin suppositories
Normalized name: Glycerin Suppositories
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerin suppositories (GS)
Study: 25900749
Drug: Dalteparin 5000
Normalized name: dalteparin 5000 intl units/0.2 mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin 5000 units once daily for 2 weeks
Study: 20848523
Drug: Traditional non-biologic
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional non-biologic therapies
Study: 9115917
Drug: Water exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water exposure (15 min twice daily for 2 weeks)
Study: 3310576
Drug: Diltiazem (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (mean 216 mg/day)
Study: 3310576
Drug: Atenolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (mean 80 mg/day)
Study: 15458233
Drug: LIG-2 (1%w/w
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIG-2 (1%w/w IDU in 5%w/w HPMC K4M gel base)
Study: 15458233
Drug: LIG-1 (1%w/w
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIG-1 (1%w/w IDU in 2%w/w HPMC K4M gel base)
Study: 11275394
Drug: St. John's
Normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St. John's wort (3 tablets each containing 900 microg total hypericin, for 5 weeks)
Study: 9395363
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil (125 mg/day)
Study: 9395363
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil (250 mg/day)
Study: 3555585
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg plus hydrochlorothiazide 25 mg, given twice daily for 1 month
Study: 3555585
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg plus hydrochlorothiazide 25 mg, given once daily for 1 month
Study: 3555585
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg plus hydrochlorothiazide 25 mg, given once or twice daily for 2 months
Study: 31703750
Drug: Training therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training therapy
Study: 28691640
Drug: n-3 supplements
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 supplements
Study: 12826020
Drug: Sulphaphenazole (0.02-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphaphenazole (0.02-2 mg/min)
Study: 12826020
Drug: Sulphaphenazole (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphaphenazole (6 mg/min) after L-NMMA (16 micromol/min) and ibuprofen (1200 mg, orally)
Study: 12826020
Drug: L-NMMA (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (4 micromol/min) and ibuprofen (1200 mg, orally)
Study: 8925987
Drug: Short parenteral
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short parenteral treatment with antibiotics (exact dosage and duration not specified)
Study: 8925987
Drug: Conventional long
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional long course treatment with antibiotics (exact dosage and duration not specified)
Study: 6693780
Drug: Encapsulated liquid
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated liquid preparation of 8‐MOP
Study: 30147307
Drug: Fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/salmeterol (FP/SAL) 250/50 µg
Study: 30147307
Drug: Tiotropium bromide
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiotropium bromide (TIO) 18 µg
Study: 25821315
Drug: IFNα2a, RBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNα2a, RBV and Q‐e‐I (5 g, orally, thrice daily in divided doses)
Study: 24219376
Drug: 1.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g/day of ResistAid
Study: 24219376
Drug: 4.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 g/day of ResistAid
Study: 19767527
Drug: Oral antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antioxidant (AO) cocktail (vitamins C and E and alpha-lipoic acid)
Study: 11463595
Drug: NO inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO inhalation at 5 ppm in supine position (SP + NO)
Study: 11463595
Drug: NO inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO inhalation in supine position (SP + NO) for Pu ARDS
Study: 11463595
Drug: NO inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO inhalation in prone position (PP + NO) for Pu ARDS
Study: 9529407
Drug: Active ultrasound
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active ultrasound treatment (1 MHz, 1.0 W/cm2, pulsed mode 1:4, 15 minutes per session)
Study: 27014353
Drug: Amlodipine/Valsartan 5/160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/Valsartan 5/160 mg
Study: 24762683
Drug: 7-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day triple regimen (rabeprazole 10 mg, amoxicillin 1000 mg, furazolidone 100 mg twice daily for 7 days)
Study: 24762683
Drug: 10-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day triple regimen (rabeprazole 10 mg, amoxicillin 1000 mg, furazolidone 100 mg twice daily for 10 days)
Study: 24762683
Drug: 7-day quadruple
Normalized name: HUMAN PULMONARY SURFACTANT-ASSOCIATED PROTEIN D (PSPD, SURFACTANT PROTEIN D, SP-D, COLLECTIN-7, SURFACTANT PROTEIN D), NON-COVALENT QUADRUPLE TRIMER, PRODUCED IN HUMAN MYELOGENOUS LEUKEMIA K562 CELLS, GLYCOFORME ALFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day quadruple regimen (rabeprazole 10 mg, bismuth 220 mg, amoxicillin 1000 mg, furazolidone 100 mg twice daily for 7 days)
Study: 24762683
Drug: 10-day quadruple
Normalized name: HUMAN PULMONARY SURFACTANT-ASSOCIATED PROTEIN D (PSPD, SURFACTANT PROTEIN D, SP-D, COLLECTIN-7, SURFACTANT PROTEIN D), NON-COVALENT QUADRUPLE TRIMER, PRODUCED IN HUMAN MYELOGENOUS LEUKEMIA K562 CELLS, GLYCOFORME ALFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day quadruple regimen (rabeprazole 10 mg, bismuth 220 mg, amoxicillin 1000 mg, furazolidone 100 mg twice daily for 10 days)
Study: 20142631
Drug: HOMA, QUICKI,
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOMA, QUICKI, fasting glucose/insulin ratio, McAuley index
Study: 10052877
Drug: Measured portal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measured portal dose images (PDIs) for lateral fields
Study: 10052877
Drug: Measured portal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measured portal dose images (PDIs) for anterior fields
Study: 10052877
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of measured and predicted portal doses for lateral fields
Study: 10052877
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of measured and predicted portal doses for anterior fields
Study: 10052877
Drug: Off-axis differences
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Off-axis differences in measured and predicted portal doses
Study: 10052877
Drug: Detection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of gas pockets during treatment